# Eclincloud

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eclincloud

- Industry: Healthcare
- Headquarters: Ningbo, China
- Website: www.eclincloud.com
- Latest round: Series B (Mar 21, 2025)
- Investors on record: 2

## About

Established in 2020 and based in Ningbo, China, Eclincloud operates as a clinical research cloud platform service provider that provides clinical cloud platform and solutions. Signant Health is the strategic partner of the company. The company cooperates with Nanjing CR Medicon Technology Co., Ltd. Mr. Michael Qin once served as biostatistician of PAREXEL International Corporation. In August 2025, Eclincloud raised a series A funding from new investor NTG Tongshang Holding Group.. The company has offices in Shenzhen, Beijing and Shanghai. The company provides clinical cloud platform and solutions for pharmaceutical enterprises, medical device companies, and research institutions. The solutions of the company include electronic informed consent (eConsent), electronic data capture (EDC), randomization and trial supply management (RTSM), electronic clinical outcome assessment (eCOA) and clinical trial management system (CTMS). The company will increase investment in researching and developing product, construct clinical data team and improve after-sales service. The company’s revenue is generated by providing an intelligent integrated cloud platform. The company will use the funding to accelerate in-depth research and development and innovative applications of AI technology, and to help expand its global strategic layout.

## Funding rounds

- Series B, Mar 21, 2025 — Hongfeng Venture
- Series A, Dec 1, 2021 — Kangjun Capital

## Investors

- Kangjun Capital (https://capitalatlas.ai/funds/kangjun-capital) — Series A
- Hongfeng Venture (https://capitalatlas.ai/funds/hongfeng-venture) — Series B